Posted by Michael Wonder on 08 Sep 2022
Ceribell receives FDA breakthrough device designation for delirium indication
8 September 2022 - Breakthrough device designation recognizes Ceribell's point of care EEG as a first of its kind technology for the detection of delirium.
Ceribell announced today that it has received breakthrough device designation for its delirium indication from the US FDA.
